
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is in a strong position with a successful Papzimeos launch, potential label expansions, and a pipeline of promising treatments. The company's financial outlook is positive with revenue growth projected for the coming years and a clear path to reaching cash flow break-even by the end of 2026. Risks to this outlook include setbacks in clinical trials, potential regulatory challenges, and competition in the market. However, overall, Precigen's strong product portfolio and strategic position make it a promising investment opportunity.
Bears say
Precigen is facing several challenges with its pipeline, including delays in data release, lack of diversity in its development programs, and potential competition in the immuno-oncology and gene therapy fields. With weak financial performance and a lack of compelling data, it is uncertain if Precigen's technology platforms can deliver on its promise to revolutionize precision medicine, making it a risky investment opportunity. As a result, a negative outlook is warranted for Precigen's stock.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares